Medical - Distribution
Compare Stocks
5 / 10Stock Comparison
MCK vs CVS vs UNH vs CAH vs CI
Revenue, margins, valuation, and 5-year total return — side by side.
Medical - Healthcare Plans
Medical - Healthcare Plans
Medical - Distribution
Medical - Healthcare Plans
MCK vs CVS vs UNH vs CAH vs CI — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||||
|---|---|---|---|---|---|
| Industry | Medical - Distribution | Medical - Healthcare Plans | Medical - Healthcare Plans | Medical - Distribution | Medical - Healthcare Plans |
| Market Cap | $92.15B | $111.40B | $335.60B | $43.59B | $74.85B |
| Revenue (TTM) | $403.43B | $407.90B | $449.71B | $250.55B | $277.94B |
| Net Income (TTM) | $4.76B | $2.93B | $12.04B | $1.56B | $6.29B |
| Gross Margin | 3.6% | 13.9% | 18.8% | 3.7% | 9.3% |
| Operating Margin | 1.5% | 1.5% | 4.2% | 0.9% | 3.4% |
| Forward P/E | 19.3x | 12.2x | 20.2x | 17.9x | 9.4x |
| Total Debt | $7.39B | $93.59B | $78.39B | $9.35B | $31.46B |
| Cash & Equiv. | $5.69B | $8.51B | $24.36B | $3.87B | $7.68B |
MCK vs CVS vs UNH vs CAH vs CI — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| McKesson Corporation (MCK) | 100 | 474.1 | +374.1% |
| CVS Health Corporat… (CVS) | 100 | 133.2 | +33.2% |
| UnitedHealth Group … (UNH) | 100 | 121.3 | +21.3% |
| Cardinal Health, In… (CAH) | 100 | 338.7 | +238.7% |
| Cigna Corporation (CI) | 100 | 143.9 | +43.9% |
Price return only. Dividends and distributions are not included.
Quick Verdict: MCK vs CVS vs UNH vs CAH vs CI
Each card shows where this stock fits in a portfolio — not just who wins on paper.
MCK has the current edge in this matchup, primarily because of its strength in growth exposure and long-term compounding.
- Rev growth 16.2%, EPS growth 14.9%, 3Y rev CAGR 10.8%
- 348.1% 10Y total return vs CAH's 160.8%
- 16.2% revenue growth vs CAH's -1.9%
- 5.7% ROA vs CVS's 1.1%, ROIC 5.4% vs 5.0%
CVS is the #2 pick in this set and the best alternative if dividends and momentum is your priority.
- 3.1% yield, vs UNH's 2.4%
- +34.7% vs CI's -13.3%
UNH ranks third and is worth considering specifically for quality.
- 2.7% margin vs CAH's 0.6%
CAH is the clearest fit if your priority is income & stability and sleep-well-at-night.
- Dividend streak 20 yrs, beta 0.03, yield 1.1%
- Lower volatility, beta 0.03, current ratio 0.94x
- Beta 0.03, yield 1.1%, current ratio 0.94x
- Beta 0.03 vs UNH's 0.59
CI is the clearest fit if your priority is value.
- Lower P/E (9.4x vs 17.9x)
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 16.2% revenue growth vs CAH's -1.9% | |
| Value | Lower P/E (9.4x vs 17.9x) | |
| Quality / Margins | 2.7% margin vs CAH's 0.6% | |
| Stability / Safety | Beta 0.03 vs UNH's 0.59 | |
| Dividends | 3.1% yield, vs UNH's 2.4% | |
| Momentum (1Y) | +34.7% vs CI's -13.3% | |
| Efficiency (ROA) | 5.7% ROA vs CVS's 1.1%, ROIC 5.4% vs 5.0% |
MCK vs CVS vs UNH vs CAH vs CI — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
MCK vs CVS vs UNH vs CAH vs CI — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
UNH leads in 1 of 6 categories
CI leads 1 • MCK leads 1 • CVS leads 0 • CAH leads 0 • 3 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
UNH leads this category, winning 4 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
UNH is the larger business by revenue, generating $449.7B annually — 1.8x CAH's $250.5B. Profitability is closely matched — net margins range from 2.7% (UNH) to 0.6% (CAH). On growth, CAH holds the edge at +11.0% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | |||||
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $403.4B | $407.9B | $449.7B | $250.5B | $277.9B |
| EBITDAEarnings before interest/tax | $6.8B | $10.5B | $23.2B | $3.2B | $12.1B |
| Net IncomeAfter-tax profit | $4.8B | $2.9B | $12.0B | $1.6B | $6.3B |
| Free Cash FlowCash after capex | $6.0B | $7.4B | $19.7B | $4.4B | $7.7B |
| Gross MarginGross profit ÷ Revenue | +3.6% | +13.9% | +18.8% | +3.7% | +9.3% |
| Operating MarginEBIT ÷ Revenue | +1.5% | +1.5% | +4.2% | +0.9% | +3.4% |
| Net MarginNet income ÷ Revenue | +1.2% | +0.7% | +2.7% | +0.6% | +2.3% |
| FCF MarginFCF ÷ Revenue | +1.5% | +1.8% | +4.4% | +1.8% | +2.8% |
| Rev. Growth (YoY)Latest quarter vs prior year | +6.0% | +6.2% | +2.0% | +11.0% | +4.6% |
| EPS Growth (YoY)Latest quarter vs prior year | +37.0% | +63.1% | +0.7% | -19.5% | +29.1% |
Valuation Metrics
CI leads this category, winning 4 of 6 comparable metrics.
Valuation Metrics
At 12.8x trailing earnings, CI trades at a 80% valuation discount to CVS's 62.8x P/E. On an enterprise value basis, CI's 8.4x EV/EBITDA is more attractive than MCK's 18.7x.
| Metric | |||||
|---|---|---|---|---|---|
| Market CapShares × price | $92.1B | $111.4B | $335.6B | $43.6B | $74.9B |
| Enterprise ValueMkt cap + debt − cash | $93.8B | $196.5B | $389.6B | $49.1B | $98.6B |
| Trailing P/EPrice ÷ TTM EPS | 29.25x | 62.81x | 27.95x | 28.72x | 12.81x |
| Forward P/EPrice ÷ next-FY EPS est. | 19.28x | 12.19x | 20.19x | 17.94x | 9.36x |
| PEG RatioP/E ÷ EPS growth rate | 0.75x | — | — | — | — |
| EV / EBITDAEnterprise value multiple | 18.74x | 13.11x | 16.70x | 16.01x | 8.39x |
| Price / SalesMarket cap ÷ Revenue | 0.26x | 0.28x | 0.75x | 0.20x | 0.27x |
| Price / BookPrice ÷ Book value/share | — | 1.47x | 3.31x | — | 1.80x |
| Price / FCFMarket cap ÷ FCF | 17.63x | 14.27x | 20.88x | 23.56x | 8.92x |
Profitability & Efficiency
MCK leads this category, winning 6 of 9 comparable metrics.
Profitability & Efficiency
MCK delivers a 3.0% return on equity — every $100 of shareholder capital generates $3 in annual profit, vs $4 for CVS. CI carries lower financial leverage with a 0.75x debt-to-equity ratio, signaling a more conservative balance sheet compared to CVS's 1.24x. On the Piotroski fundamental quality scale (0–9), CI scores 8/9 vs CVS's 5/9, reflecting strong financial health.
| Metric | |||||
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | +3.0% | +3.9% | +11.5% | — | +15.1% |
| ROA (TTM)Return on assets | +5.7% | +1.1% | +3.9% | +2.8% | +4.1% |
| ROICReturn on invested capital | +5.4% | +5.0% | +9.2% | +33.8% | +10.4% |
| ROCEReturn on capital employed | +30.5% | +6.1% | +9.7% | +19.2% | +9.2% |
| Piotroski ScoreFundamental quality 0–9 | 6 | 5 | 6 | 6 | 8 |
| Debt / EquityFinancial leverage | — | 1.24x | 0.77x | — | 0.75x |
| Net DebtTotal debt minus cash | $1.7B | $85.1B | $54.0B | $5.5B | $23.8B |
| Cash & Equiv.Liquid assets | $5.7B | $8.5B | $24.4B | $3.9B | $7.7B |
| Total DebtShort + long-term debt | $7.4B | $93.6B | $78.4B | $9.3B | $31.5B |
| Interest CoverageEBIT ÷ Interest expense | 33.79x | 2.11x | 4.71x | 6.38x | 6.77x |
Total Returns (Dividends Reinvested)
Evenly matched — MCK and CVS and CAH each lead in 2 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in MCK five years ago would be worth $38,689 today (with dividends reinvested), compared to $9,743 for UNH. Over the past 12 months, CVS leads with a +34.7% total return vs CI's -13.3%. The 3-year compound annual growth rate (CAGR) favors CAH at 31.5% vs UNH's -7.1% — a key indicator of consistent wealth creation.
| Metric | |||||
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | -8.5% | +10.6% | +10.6% | -9.5% | +2.3% |
| 1-Year ReturnPast 12 months | +4.6% | +34.7% | -3.2% | +22.0% | -13.3% |
| 3-Year ReturnCumulative with dividends | +106.4% | +36.6% | -19.9% | +127.3% | +13.6% |
| 5-Year ReturnCumulative with dividends | +286.9% | +17.0% | -2.6% | +235.7% | +18.5% |
| 10-Year ReturnCumulative with dividends | +348.1% | +3.5% | +220.6% | +160.8% | +136.5% |
| CAGR (3Y)Annualised 3-year return | +27.3% | +11.0% | -7.1% | +31.5% | +4.4% |
Risk & Volatility
Evenly matched — CVS and CAH each lead in 1 of 2 comparable metrics.
Risk & Volatility
CAH is the less volatile stock with a 0.03 beta — it tends to amplify market swings less than UNH's 0.59 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. CVS currently trades 98.5% from its 52-week high vs MCK's 75.3% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||||
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.04x | 0.05x | 0.59x | 0.03x | 0.35x |
| 52-Week HighHighest price in past year | $999.00 | $88.63 | $395.52 | $233.60 | $338.89 |
| 52-Week LowLowest price in past year | $637.00 | $58.35 | $234.60 | $137.75 | $239.51 |
| % of 52W HighCurrent price vs 52-week peak | +75.3% | +98.5% | +93.5% | +79.3% | +83.8% |
| RSI (14)Momentum oscillator 0–100 | 16.2 | 69.3 | 75.9 | 33.2 | 53.5 |
| Avg Volume (50D)Average daily shares traded | 757K | 7.4M | 7.9M | 1.7M | 1.5M |
Analyst Outlook
Evenly matched — CVS and UNH each lead in 1 of 2 comparable metrics.
Analyst Outlook
Analyst consensus: MCK as "Buy", CVS as "Buy", UNH as "Buy", CAH as "Buy", CI as "Buy". Consensus price targets imply 34.8% upside for CAH (target: $250) vs 4.2% for UNH (target: $385). For income investors, CVS offers the higher dividend yield at 3.06% vs MCK's 0.36%.
| Metric | |||||
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | $1006.50 | $95.20 | $385.43 | $249.67 | $328.00 |
| # AnalystsCovering analysts | 31 | 41 | 52 | 33 | 39 |
| Dividend YieldAnnual dividend ÷ price | +0.4% | +3.1% | +2.4% | +1.1% | +2.1% |
| Dividend StreakConsecutive years of raises | 17 | 0 | 25 | 20 | 6 |
| Dividend / ShareAnnual DPS | $2.69 | $2.67 | $8.70 | $2.04 | $6.06 |
| Buyback YieldShare repurchases ÷ mkt cap | +3.4% | 0.0% | +1.7% | +1.8% | +4.8% |
UNH leads in 1 of 6 categories (Income & Cash Flow). CI leads in 1 (Valuation Metrics). 3 tied.
MCK vs CVS vs UNH vs CAH vs CI: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is MCK or CVS or UNH or CAH or CI a better buy right now?
For growth investors, McKesson Corporation (MCK) is the stronger pick with 16.
2% revenue growth year-over-year, versus -1. 9% for Cardinal Health, Inc. (CAH). Cigna Corporation (CI) offers the better valuation at 12. 8x trailing P/E (9. 4x forward), making it the more compelling value choice. Analysts rate McKesson Corporation (MCK) a "Buy" — based on 31 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — MCK or CVS or UNH or CAH or CI?
On trailing P/E, Cigna Corporation (CI) is the cheapest at 12.
8x versus CVS Health Corporation at 62. 8x. On forward P/E, Cigna Corporation is actually cheaper at 9. 4x.
03Which is the better long-term investment — MCK or CVS or UNH or CAH or CI?
Over the past 5 years, McKesson Corporation (MCK) delivered a total return of +286.
9%, compared to -2. 6% for UnitedHealth Group Incorporated (UNH). Over 10 years, the gap is even starker: MCK returned +348. 1% versus CVS's +3. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — MCK or CVS or UNH or CAH or CI?
By beta (market sensitivity over 5 years), Cardinal Health, Inc.
(CAH) is the lower-risk stock at 0. 03β versus UnitedHealth Group Incorporated's 0. 59β — meaning UNH is approximately 1630% more volatile than CAH relative to the S&P 500. On balance sheet safety, Cigna Corporation (CI) carries a lower debt/equity ratio of 75% versus 124% for CVS Health Corporation — giving it more financial flexibility in a downturn.
05Which is growing faster — MCK or CVS or UNH or CAH or CI?
By revenue growth (latest reported year), McKesson Corporation (MCK) is pulling ahead at 16.
2% versus -1. 9% for Cardinal Health, Inc. (CAH). On earnings-per-share growth, the picture is similar: Cardinal Health, Inc. grew EPS 87. 0% year-over-year, compared to -62. 0% for CVS Health Corporation. Over a 3-year CAGR, CI leads at 15. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — MCK or CVS or UNH or CAH or CI?
UnitedHealth Group Incorporated (UNH) is the more profitable company, earning 2.
7% net margin versus 0. 4% for CVS Health Corporation — meaning it keeps 2. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: UNH leads at 4. 2% versus 1. 0% for CAH. At the gross margin level — before operating expenses — UNH leads at 18. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is MCK or CVS or UNH or CAH or CI more undervalued right now?
On forward earnings alone, Cigna Corporation (CI) trades at 9.
4x forward P/E versus 20. 2x for UnitedHealth Group Incorporated — 10. 8x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for CAH: 34. 8% to $249. 67.
08Which pays a better dividend — MCK or CVS or UNH or CAH or CI?
All stocks in this comparison pay dividends.
CVS Health Corporation (CVS) offers the highest yield at 3. 1%, versus 0. 4% for McKesson Corporation (MCK).
09Is MCK or CVS or UNH or CAH or CI better for a retirement portfolio?
For long-horizon retirement investors, Cardinal Health, Inc.
(CAH) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 03), 1. 1% yield, +160. 8% 10Y return). Both have compounded well over 10 years (CAH: +160. 8%, UNH: +220. 6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between MCK and CVS and UNH and CAH and CI?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: MCK is a mid-cap high-growth stock; CVS is a mid-cap income-oriented stock; UNH is a large-cap quality compounder stock; CAH is a mid-cap quality compounder stock; CI is a mid-cap deep-value stock. CVS, UNH, CAH, CI pay a dividend while MCK does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.